These two large caps look seriously undervalued

These two large caps could be the most undervalued in the FTSE 100.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s rare to find undervalued large caps outside a recession. Large caps are so well covered by City analysts and the financial press, any company that becomes undervalued is soon snapped up by investors and the special offer quickly disappears.

However, there are currently two businesses in the FTSE 100 that looked undervalued relative to their international peers. These companies are some of the largest in the industry and have a reputation for steady growth and defensive dividends.

Growth and dividends

AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) are the two undervalued large caps in question. These two pharmaceuticals giants have seen their shares rally sharply since the beginning of the year, but recently investors have started to book profits and the shares have given up some of their recent gains. Still, the fundamentals of these companies haven’t changed over the past few weeks. Glaxo and Astra remain attractive on several different metrics.

Firstly, Glaxo and Astra are both trading at extremely attractive P/E multiples compared to their international peers. While many of these firms’ international peers trade at P/E multiples of 20 more, these two UK giants currently trade at P/E multiples in the mid-teens. Shares in Glaxo trade at a forward P/E multiple of 16.5 and Astra’s shares trade at a forward P/E multiple of 15.6.

There’s a reason why investors are giving Astra wide berth. This year the company loses its exclusive manufacturing rights to blockbuster drug Crestor, and it looks as if the market is waiting to see how quickly sales deteriorate following this key landmark. City analysts have pencilled-in an earnings decline of 1% for 2016 and 3% for 2017 as Crestor sales fall and other treatments pick up the slack.

On the other hand, there’s no apparent reason why Glaxo’s shares are trading at a discount to international peers. If anything, shares in the company should be trading at a premium to international competitors and the wider market. 

City analysts expect earnings per share growth of 27% for this year and 7% for 2017. Based on this year’s growth forecast, shares in the company are trading at a PEG ratio of 0.6. A PEG ratio of less than one indicates that the shares offer growth at a reasonable price, yet another indicator that Glaxo is undervalued.

Top income picks 

Another metric that shows just how undervalued these two stocks are is the dividend yield. Technically, if a share’s dividend yield is above the market average, it implies that the market believes the payout isn’t sustainable. The FTSE 100 average dividend yield is 3.8% and at time of writing, shares in Glaxo and Astra both support a higher yield. 

Astra’s shares yield 4.4%, and Glaxo’s shares 5.1%. But both payouts are well covered by earnings per share.

In today’s low-interest-rate world, few large cap companies yield more than the market average making Astra and Glaxo a rare breed indeed.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »